Anti-CXCL1/GRO alpha antibody [EPR19892]
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(9 Publications)
Rabbit Recombinant Monoclonal CXCL1/GRO alpha antibody. Suitable for IP, WB and reacts with Human, Recombinant fragment - Human samples. Cited in 9 publications.
View Alternative Names
GRO, GRO1, GROA, MGSA, SCYB1, CXCL1, Growth-regulated alpha protein, C-X-C motif chemokine 1, GRO-alpha(1-73), Melanoma growth stimulatory activity, Neutrophil-activating protein 3, NAP-3
- IP
Lab
Immunoprecipitation - Anti-CXCL1/GRO alpha antibody [EPR19892] (AB206411)
11 kDa CXCL1/GRO alpha was immunoprecipitated from 0.35mg of HUVEC (human umbilical vein endothelial cell) whole cell lysate with ab206411 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab206411 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/5000 dilution. Lane 1 (Input) : HUVEC treated with 0.5 μg/ml LPS for 4 hours, then added 300 ng/ml BFA for another 20 hours whole cell lysate 10 μg. Lane 2 (+) : ab206411-IP in HUVEC treated with 0.5 μg/ml LPS for 4 hours, then added 300 ng/ml BFA for another 20 hours whole cell lysate. Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab206411 in HUVEC treated as above whole cell lysate. Blocking buffer and concentration : 5% NFDM/TBST. Diluting buffer and concentration : 5% NFDM/TBST. Exposure time : 180 seconds.
All lanes:
Immunoprecipitation - Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411)
Lane 1:
HUVEC (human umbilical vein endothelial cell) treated with 0.5 μg/ml LPS for 4 hours, then added 300 ng/ml BFA for another 20 hours whole cell lysate at 10 µg
Lane 2:
HUVEC (human umbilical vein endothelial cell) treated with 0.5 μg/ml LPS for 4 hours, then added 300 ng/ml BFA for another 20 hours whole cell lysate
Secondary
All lanes:
Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
false
- WB
Supplier Data
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (AB206411)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/100 dilution
All lanes:
Human fetal lung lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
false
Exposure time: 3min
- WB
Supplier Data
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (AB206411)
Blocking/Dilution buffer : 5% NFDM/TBST.
Human GRO beta fragment recombinant protein contain aa35-107 with a GST-Tag. Human GRO gamma fragment recombinant protein contain aa35-107 with a His-Tag®. These two protein were made in house.
All lanes:
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/1000 dilution
Lane 1:
Human CXCL1/GRO alpha active protein at 0.01 µg
Lane 2:
Human GRO beta fragment recombinant protein at 0.01 µg
Lane 3:
Human GRO gamma fragment recombinant protein at 0.01 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 10 kDa,36 kDa
false
Exposure time: 3min
- WB
Lab
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (AB206411)
False colour image of Western blot : Anti-CXCL1/GRO alpha antibody [EPR19892] staining at 1/100 dilution, shown in black; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab206411 was shown to bind specifically to CXCL1/GRO alpha. A band was observed at 8 kDa in treated wild-type HeLa cell lysates with no signal observed at this size in CXCL1 knockout cell line ab261774 (knockout cell lysate ab257079). To generate this image, wild-type and CXCL1 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with Optiblot (ECL reagent ab133456) and imaged with 20 minutes exposure time. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and HRP conjugated Goat anti-Mouse (H+L) at 1/20000 dilution.
All lanes:
Western blot - Anti-CXCL1/GRO alpha antibody [EPR19892] (ab206411) at 1/100 dilution
Lane 1:
Wild-type HeLa Treated TNF alpha (5 ng/mL, 6 h) + BFA (5 ug/mL, 6 h) cell lysate at 20 µg
Lane 2:
CXCL1 knockout HeLa Treated TNF alpha (5 ng/mL, 6 h) + BFA (5 ug/mL, 6 h) cell lysate at 20 µg
Lane 2:
Western blot - Human CXCL1 (GRO alpha) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-cxcl1-gro-alpha-knockout-hela-cell-line-ab261774'>ab261774</a>)
Predicted band size: 11 kDa
Observed band size: 8 kDa
false
Related conjugates and formulations (1)
-
Anti-CXCL1/GRO alpha antibody [EPR19892] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CXCL1 functions as a significant mediator in inflammatory processes. It does not form a complex but acts independently to exert its effects. By attracting neutrophils to sites of injury or infection CXCL1 supports the body's defense mechanisms. This chemokine also influences angiogenesis contributing to the formation of new blood vessels which is essential in wound healing and tissue regeneration.
Pathways
CXCL1 plays a role in both the NF-kB signaling and MAPK signaling pathways. These pathways are pivotal for the regulation of immune and inflammatory responses. CXCL1 acts alongside proteins such as IL-8 another chemokine that also binds to the CXCR2 receptor. Through these pathways CXCL1 influences the activation and migration of immune cells facilitating a rapid response to inflammatory stimuli.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (9)
Recent publications for all applications. Explore the full list and refine your search
Biomedical reports 23:111 PubMed40386306
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of inflammation research 17:6863-6874 PubMed39372590
2024
Applications
Unspecified application
Species
Unspecified reactive species
Discover oncology 15:145 PubMed38713320
2024
Applications
Unspecified application
Species
Unspecified reactive species
Immunity, inflammation and disease 12:e1157 PubMed38415976
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 9:253 PubMed37468464
2023
Applications
Unspecified application
Species
Unspecified reactive species
Asian Pacific journal of cancer prevention : APJCP 23:3843-3849 PubMed36444597
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of clinical laboratory analysis 36:e24232 PubMed34995016
2022
Applications
Unspecified application
Species
Unspecified reactive species
Bioengineered 12:9909-9917 PubMed34860147
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 11:665080 PubMed34123826
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com